MarketInOut Stock Screener Log In | Sign Up

Inventiva S.A.

PAR • Healthcare • Biotechnology • Quote as of 10/30/2026
Inventiva S.A. stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangePAR
Market Capitalization751.18 mln
Float163 mln
Earnings Date03/31/2027

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

-7.69
Highly reliable

1-Year Forecast

9.77
Transformational upside

Relative Strength

98 / 100
Top performer

Debt / Equity

1.13
Elevated leverage

Pre-Tax Margin

-508,308%
Severely loss-making

Business Description

Inventiva S.A. is a French pharmaceutical company founded in 2011 that creates pill-based treatments for serious diseases, with operations extending beyond France to international markets. Its most advanced drug, Lanifibranor, is currently being tested in a large-scale clinical trial as a potential treatment for a severe liver condition known as MASH, while a second drug, Odiparcil, targets a rare inherited disorder affecting the body's ability to break down certain sugars. The company is also in the early stages of researching a treatment for a progressive lung disease called idiopathic pulmonary fibrosis.

Key Fundamentals

EPS-0.53
ROE-3,606
RPS0.01
ROIC-220
ROA-109
Interest Cover-3.92
EBITDA, mln-208
EV / EBITDA-3.96
EV / EBIT-3.91
Revenue, mln0.05
EV / Revenue16,810

Quote Details

Last 3.18
Change -0.17 (-5.07%)
Open 3.32
Volume 443,082
Turnover 1,409,001
Average Volume 565,171

Financial Ratios

Pre-Tax Profit Margin-508,308
Leverage Ratio4.26
Current Ratio3.81
Price / Book13.10
Price / Tangible Book13.10
Debt / Equity1.13
Price / Sales136

Financial Strength

Altman Z-Score-1.72
Piotroski F-Score 3 / 9
Beneish M-Score-7.69
1-Year Target Price9.77

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 3.92% 87 / 100   
1 Month 4.26% 83 / 100   
2 Months -19.08% 13 / 100   
6 Months -29.49% 12 / 100   
1 Year -13.59% 28 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog